This is the authors' abstract. We don't add key points for this paper.
Dexamethasone may be a better partner for abiraterone compared with prednisolone in the treatment of metastatic castration-resistant prostate cancer. Upfront use of dexamethasone with abiraterone or a switch from prednisolone to dexamethasone at prostate-specific antigen progression might be feasible options and are currently being tested in larger trials.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Ömer Dızdar (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: